Clinical Trials

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits. Subjects with vitiligo will be required to follow up for additional specimen collection and questionnaire completion after six months and one year.

The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship between the burden and how severe or visible the skin problem is.​ Surveys can be done remotely.

Psoriasis is a skin condition that causes red, scaly, itchy patches on the skin. Psoriasis is associated with inflammation that may play a role in heart disease, stroke, diabetes, obesity and other metabolic disease. Lipoproteins (substances made up of fat and protein), cholesterol, and other proteins associated with inflammation have specifically been shown to be abnormal in psoriasis patients. The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of these inflammatory substances and lipoproteins in the blood. If systemic therapy is shown to improve levels of these substances in the blood,it may indicate prevention against the development of heart disease, stroke,diabetes, obesity and other metabolic disease. Subjects will be required to have one fasting blood draw for collection of research samples. 

Psoriasis is a skin condition that causes red, scaly, itchy patches. There is a gene called CARD14 and some mutations in CARD14 cause psoriasis in both children and adults. These mutations can be passed down from parents to children in families, but a child with no family history of psoriasis could also have a new mutation in CARD14 that causes psoriasis.

The purpose of this study is to see what kinds of mutations in the CARD14 gene cause psoriasis and what new mutations in other genes can cause psoriasis in a child with no family history of psoriasis. Participants will be assessed for demographics, clinical, medication, and family history as well as severity of psoriasis at the study visit (in-clinic or over the phone). Saliva samples or buccal swabs will be obtained from all subjects.

PEDISTAD is an observational study to assess the features of children with moderate to severe atopic dermatitis, also called eczema,whose disease is not adequately controlled with topical therapies (creams orlotions) or when those therapies are not medically advisable.

Participants in this non-interventional study will be treated in the usual way for their conditions and will not undergo extra tests. The study will document how atopic dermatitis and other diseases linked to atopic dermatitis changes over time and will also investigate the influence of routine clinical practice on clinical results to understand how atopic dermatitis affects children and their caregivers in their daily lives. There is an optional, additional study that will also enroll subjects for the collection of research specimens during regularly scheduled clinic appointments for biomarker analysis. 

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another.

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo option. Theeffectiveness and safety of the treatment will be determined by a range of assessments,including biopsies, images, and subjective evaluation of perceived hair growth.

Epidermolysis bullosa(EB) is a group of genetic conditions that cause blistering of the skin. In the Junctional EB (JEB) and Dystrophic EB (DEB) subtypes, EB wounds do not heal easily and can result in permanent and disfiguring scarring. The experimental drug in this study, a Tβ4 topical gel, is being tested in these two subtypes because of Tβ4’s wound healing characteristics. The study will compare how well 0.03% RGN-137 (Tβ4 topical gel)works and how safe it is compared to a placebo gel (which looks like the study drug but does not have any active drug ingredient) in the treatment of JEB or DEB.

Alopecia Areata is much more than losing your hair. It’s an autoimmune condition that can cause severe emotional distress, including depression and anxiety  - and can get in the way of living a full life. There are no FDA approved treatments for Alopecia Areata, but researchers are working hard to change that. A clinical research study is now underway throughout the country– and is seeking volunteers with Alopecia Areata affecting at least half of their scalp to participate. Qualified participants will receive study-related care and investigational medication at no cost to them. 

LP0133-1275 is a clinical research study that will testdifferent strengths of the investigational study drug “delgocitinib” for the treatmentof mild to severe atopic dermatitis. In this study, you will get assigned toapply (twice daily for 8 weeks) 1 mg, 3 mg, 8 mg, 20 mg of delgocitinib cream,or you will be assigned to apply a delgocitinib cream vehicle (placebo). Theeffectiveness and safety of delgocitinib will be judged by a range ofassessments that rate the severity and extent of atopic dermatitis, itch andseveral other symptoms, as well as general health status and quality of life.

This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treating patients with an aggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that hasnot responded to or has come back after other treatments. The effectiveness and safety of the treatment will be determined by a range of assessments including biopsies, scans (or imaging tests), as well as general health and performance status.